Office of Clinical Trials Research

Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The trial will enroll a total of 28 healthy, non-pregnant adults ages 18 to 50 at the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore, Md., and at the Vaccine Testing Center at the Larner College of Medicine at the University of Vermont in Burlington.

On February 7, 2018, The Burlington Free interviewed Emily Tarleton, Ph.D., bionutrition research manager at the UVM Clinical Research Center, about a recent clinical trial conducted at the College relating to use of magnesium for treatment of mild to moderate depression.

Vermont is among the top ten states in per capita research funding in the U.S., according to a State of Research at the College presentation delivered by Larner College of Medicine Senior Associate Dean for Research Gordon Jensen, M.D., Ph.D., at the Dean’s Excellence in Research Awards event held November 13, 2017. The last of three 2017 Celebrating Excellence in Research events held at the College on November 10 and 13, 2017, the awards ceremony recognized the accomplishments of faculty, residents, medical students, graduate students and postdoctoral trainees.

A five-year, $20 million National Institutes of Health (NIH) Clinical and Translational Research (CTR) Network grant will fund a joint program between the University of Vermont (UVM) and Maine Medical Center in Portland, Maine to develop and sustain a clinical and translational research infrastructure improving rural and community health for residents of Vermont, New Hampshire and Maine.